Early-stage companies seeking seed and Series A stage investments will be invited to apply in September through the Spex Capital Call
The most promising candidates will be offered tickets between £500,000 and £5,000,000
Spex Capital, the specialist digital health and medtech investment firm, has joined forces with MedCity to identify and fund promising health tech ventures, accelerating their route to commercialisation and uptake in healthcare systems globally. The exclusive partnership will support several calls for innovative companies seeking investment, with the first call launching in September focussing on companies wanting seed and Series A stage investment.
As the life sciences cluster organisation for London, MedCity has well-established relationships across the UK ecosystem and with international life science clusters. Under the new partnership with Spex Capital, MedCity will use its extensive networks and expertise to attract applications from investment-ready companies developing breakthrough digital health tech and medtech.
The investment firm will invest in the most viable of those companies, and with a £100 million fundraising target, Spex Capital will truly implement change in digital healthcare. The most promising companies will be offered tickets between £500k and £5 millions.
Founded in 2021 by serial health tech entrepreneur Claudio D’Angelo, London-based Spex Capital already has a portfolio of seven high-growth companies.
“There is an incredible pool of talent with unexpressed potential in digital health and med tech, but many innovative ventures in the sector don’t get access to the appropriate opportunities in their early stages due to lack of funds and track record.” comments Spex Capital Founder and Managing Director Claudio D’Angelo. “This is where Spex Capital comes in. Specialised in advancing disruptive early-stage ventures, our goal is to deliver breakthroughs in healthcare systems globally. I’m glad to be working again with MedCity on an exclusive basis with my new venture. We’ve fine-tuned the process over the years to deliver a more efficient reviewal process and I’m excited to see what this call will yield in terms of talent”
MedCity COO Nicki Bromwich views the partnership as a natural alignment of shared interests: “Through its funding of transformative health tech, Spex Capital is allied with MedCity’s own mission of supercharging innovation and driving investment into the life sciences sector to ultimately improve human health and patient outcomes. “
Spex Capital launched earlier this year, with a strong team of fifteen in place. Made up of six investment team members, seven senior advisors and two venture partners, the team has been carefully chosen on the calibre of their backgrounds and complementary skills in the sector.
Based in London and leveraging its global reach in the sector, Spex Capital is unique in its genre for the international proposition it offers to health-tech entrepreneurs and investors. Ahead of launch, the firm has already established a world-class ecosystem via partnerships and relationships with accelerators and incubators, universities, hospitals, embassies, chambers of commerce, trade bodies, payors and healthcare systems across all continents to source the highest quality technologies worldwide.